The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given ...

But there are many questions left to answer, not least what the future holds for weight-loss medications and society at large ...

The PRAC still has another safety review on the go for the GLP-1 class ... can be caused by Ozempic and Mounjaro (tirzepatide), Lilly’s dual GLP-1/GIP agonist. A formulation of MSD's cancer ...